Loading
Impedimed Limited Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest was filed 03 Jun 2026.
Impedimed Limited: what insiders have been doing
Every trade that managers of Impedimed Limited disclose to ASX is tracked on this page. The company sits in the Health Care sector and is based in Australia. It was founded in 1999. Between 18 October 2025 and 18 October 2026, 3 insiders published 7 filings.
Only purchases show up on the open market, 5 purchases in all, filed by 1 insider. No amount is published for 5 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive.
Compared with its exchange (2,527 companies, median 3 filings), a count of 7 filings is above the norm. Since 2026, the database holds 5 purchases and no sales by insiders of the company.
The latest purchase dates back some time: it was published 137 days ago, on 3 June 2026.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Australia · Founded: 1999
Source: Wikidata (CC0).
Insider Decl.
7
Thresholds
n/a
Buy Volume
n/a
5 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleUnknown5 buys
Since the insiders bought
- Unknown-14.3%Entry A$0.01 · Close 15 Oct 2026 A$0.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 21,158 of 24,161 companies
24.6
score / 100
Value2
Quality48
FCF yld-87%
Earn yld-113%
EV/EBITDA·
ROE-162%
Gross mgn87%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.01
Analyst consensus
4 analysts1.25/5
A$0.01Target A$0.02(+199%)A$0.04
Income statement
RevenueA$14.6M
Gross profitA$12.8M87% margin
EBITDA-A$16.3M-112% margin
Net income-A$24.9M-170.4% margin
Valuation
PER (forward)-3.8x
P/Book2.3x
Beta1.07
Balance sheet & cash
Market capA$25.6M
Total debtA$16.6M
Free Cash Flow-A$19.1M
Debt / Equity163%
Profitability & ownership
ROE-162.4%
ROA-34.8%
% insiders9.2%
% institutions21.1%
Last declaration on 1 October 2026
Declarations7 total
●
ShareASXISIN AU000000IPD8ASX:2924-03143644-2A1701379
7 of 7 declarations
About Impedimed Limited
Impedimed Limited is a medical technology company focused on developing solutions for the diagnosis and management of lymphatic diseases. It is listed on the XASX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
